logo
Wedding Protesters Say Bezos Should Pay More Tax. Here's How Much He Likely Did Pay

Wedding Protesters Say Bezos Should Pay More Tax. Here's How Much He Likely Did Pay

Forbes17 hours ago

Activists from the UK-based collective "Everyone Hates Elon" and Greenpeace Italy unfurled the banner in Venice earlier this week, ahead of Jeff Bezos' and Lauren Sánchez's wedding weekend. Stefano Rellandini/AFP/Getty Images
'I f you can rent Venice for your wedding, you can pay more tax,' read a 4,300-square-foot banner unfurled across Venice's Piazza San Marco on Monday, days ahead of billionaire Amazon founder Jeff Bezos' wedding to former TV journalist Lauren Sánchez. 'This isn't just about one person—it's about changing the rules so no billionaire can dodge responsibility, anywhere,' Clara Thompson, campaigner for environmental activist organization Greenpeace (which helped organize the protest), wrote in a press release. 'The real issue is a broken system that lets billionaires skip out on their fair share of taxes while everyone else is left to foot the bill.'
So just how much in tax does Bezos really pay? The world's fourth-richest man—now worth an estimated $231 billion—likely paid some $2.7 billion in taxes in 2024, per Forbes estimates. The lion's share of that tax bill is the result of Bezos' record year of share sales: he offloaded $13.6 billion worth of Amazon stock as the e-commerce giant's share price soared 46% and pushed Bezos' net worth to an all-time high. In just one year, he got nearly $60 billion richer—meaning his taxes amounted to just 4.5% of his increase in wealth last year. (Bezos owns a nearly 9% stake in Amazon worth $203 billion.) That's because stock is only taxed when it's sold, and not on its appreciation in value; activists like the protesters in Venice this week want that to change. Bezos also donated $2.5 billion worth of Amazon shares to nonprofits over the last three years, which enabled him to reduce his 2024 tax bill by as much as an estimated $600 million.
'As long as they hold onto assets that gain in value, there's no tax, no matter how rich they are on paper,' says Brian Schultz, tax partner at wealth management and consulting firm Plante Moran. Bezos didn't pay any federal taxes in 2007 and 2011, per ProPublica reporting on leaked tax returns, and likely paid little in 2022 and 2023, two years when he didn't sell any Amazon shares. (Amazon doesn't pay dividends, which are also subject to taxes.)
The protesters in Venice say that Bezos—and billionaires like him—should be taxed on their wealth (as opposed to their income) or the appreciation of their unsold stock in order to pay their 'fair share.' Per a 2018 UC Berkeley study based on Forbes data, families in the top 0.1% of Americans by net worth were estimated to owe just 3.2% of their wealth in taxes in 2019, while the bottom 99% were estimated to have owed 7.2%; since then, America's richest have only gotten richer, and Bezos' estimated tax bill for 2024 amounts to around 1% of his estimated net worth. If some of the plans to tax billionaires more that have been proposed recently were in effect, his tax bill for last year would have likely more than tripled but would still be a small fraction of his net worth.
B ezos founded Amazon in 1994 and took it public in 1997. (Had he never parted with any of his stock, Bezos would still own a 22% stake worth more than $500 billion today.) Since then, Amazon hasn't awarded Bezos additional stock and has paid him a modest salary—$81,840 in 2020, the year before he stepped down as CEO. He's not just being humble. Having cash salaries as low as $1 is a common, tax-advantageous move among executives because, while cash income is taxed in the year the executive receives it, shares of company stock don't get taxed until they're sold for a profit. That means Bezos can defer paying taxes on the stock he's owned for decades.
In 2023, Bezos announced his move to Florida with a sentimental video his dad took of him at Amazon's first 'office' (his garage in Seattle) and Bezos explaining how he wanted to be closer to his parents, who'd recently moved back to Miami. What he didn't mention: The move also allowed him to avoid the newly-enacted 7% state capital gains tax in Washington, where he'd lived since 1994. The fact that he sold a record sum the first year he lived in Florida might be coincidental, but it saved him a bundle. The $13.6 billion from Bezos' 2024 Amazon share sales was likely subject to the top 23.8% rate for federal taxes on long-term capital gains, resulting in an estimated $3.2 billion federal tax liability before deductions. Had he still lived in Washington, he likely would have paid nearly 31%, or another $1 billion in taxes. Like Washington, Florida has no state income tax. As Bezos, 61, nears the average American's retirement age, the Sunshine State offers one other advantage: no state estate tax (and as for the federal estate tax, most billionaires are able to avoid that anyway).
Amazon share sales aside, Bezos pays a smattering of other taxes. For example, property taxes: Over the last five years, Bezos spent more than $500 million to add several splashy homes to his real estate portfolio, including three (or possibly four) properties on Miami-Dade County's 'billionaire bunker,' Beverly Hills' nine-acre Warner Estate and a secluded estate on the Hawaiian island of Maui. Bezos' properties in Florida, Washington, California, D.C., New York and Hawaii cost him around $7 million in 2024 property taxes, per local government websites. (He also sold one of his Washington state properties for $63 million last year, which resulted in around $10 million in estimated taxes.)
Bezos could pay annual taxes on other investments. Since he made a reported $250,000 bet on Google in 1998, Bezos has invested in at least 108 startups—and now holds stakes in several high-profile AI companies, including humanoid robotics firm Figure AI and AI-powered search engine Perplexity. (Dow Jones & Co. sued the company in 2023 alleging large-scale illegal copying of copyrighted work; Forbes sent Perplexity a cease-and-desist letter accusing the company of using its reporting without permission in June 2024.) If any of the companies he bet on are acquired, conduct private share sales, pay dividends or go public, Bezos would need to pay capital gains taxes on that income. Additionally, if Bezos has other income-generating investments, like dividend- or interest-paying stocks or bonds, that would add to his tax bill as well, according to Matthew Lee, director of wealth strategies at investment manager Wilmington Trust.
Then there are the tax deductions, mostly due to charitable contributions. Bezos is one of America's top givers by dollar amount, per Forbes' calculations, having given away more than $4 billion during his lifetime to climate, housing and education causes, as well as the Smithsonian and the Obama Foundation. Donors can immediately deduct up to 20% or 30% of their adjusted gross income via stock gifts to charitable organizations, regardless of whether those charities actually use the funds that year (and potentially more via charitable trusts, although Bezos isn't known to use them). Donors can also carry forward unused deductions from the past five years.
'Of course you have to have a desire to support charities,' says Plante Moran's Schultz of wealthy philanthropists. 'But if they're going to donate to charity, there's certainly incentive to try to make sure that it's as tax beneficial as possible for the money that they're looking to give.'
Here's how that likely applies to Bezos. Bezos had a capital gain of nearly $13.6 billion from selling Amazon stock in 2024. He didn't sell any Amazon stock in 2022 and 2023—when shares were down and when Washington was in the process of enacting its 7% state capital gains tax—and likely didn't report nearly as much income in those years. That means Bezos' charitable contributions from 2022 to 2024 could have been deductible on his 2024 tax return. According to securities filings, Bezos gifted $2.5 billion worth of Amazon stock to nonprofit organizations during that period—just under 20% of his estimated 2024 income. If all applied to his 2024 tax bill, the gifts could have reduced Bezos' tax obligation by as much as $600 million.
One other way the ultra-wealthy often avoid taxes is by borrowing against their shares tax-free instead of selling them, which would trigger capital gains taxes. Elon Musk, the world's richest person, famously employs this approach with his Tesla shares. Amazon discloses in regulatory filings that directors like Bezos 'may not pledge Amazon securities as collateral for a loan' unless the arrangement is 'precleared with the Legal Department.' As Amazon's executive chair, Bezos would be required to disclose pledged shares in regulatory filings, and hasn't done so. Still, he could borrow against other stocks he owns.
Proposals for taxing the ultra-wealthy more do exist. In 2021, Senator Elizabeth Warren proposed an 'Ultra-Millionaire Tax' that would impose a 6% annual wealth tax on fortunes above $1 billion, and claimed it would bring in nearly $3.75 trillion over a decade. During her 2024 presidential campaign, former vice president Kamala Harris expressed support for a proposal that people worth more than $100 million pay a minimum of 25% of their income (which would be expanded to include 'unrealized capital gains') in taxes.
Neither proposal has been successful so far. But if enacted, Forbes estimates that Bezos would have needed to pay more than $10 billion in additional taxes under either Warren's or Harris' preferred approach. Neither sum would dent his fortune much at all. 'Every handful of years, depending on the makeup in Washington, those proposals get resurrected,' says Wilmington Trust's Lee. 'But I think you're seeing more politicians who seem to be interested in exploring those.'
As for his wedding? Getting married isn't likely to affect his tax bill much, if at all. Bezos and Sánchez are so far above income thresholds that would make filing joint taxes financially advantageous for them. And especially because this isn't a first marriage for either of them, almost all property is likely to be kept separate, taxed separately and bound to a strict prenuptial agreement, regardless of whether they file taxes jointly or not, says Lauren Crane, partner at family and matrimonial law firm Bender and Crane. In any case, Bezos is certainly saving enough on tax deductions to cover the costs of his and Sanchez's star-studded wedding festivities, from canals to cakes.
More from Forbes Forbes Why The U.S. Should Copy Canada To Fix Its Broken Air Traffic Control System By Jeremy Bogaisky Forbes Will Mamdani's Proposed Millionaire Tax Save Or Sink New York City? By Kelly Phillips Erb Forbes How This Hollywood Producer Turned Brad Pitt Into A $40 Million 'F1' Ad By Matt Craig Forbes Elon Musk Has Fired One Of His Top Tesla Lieutenants By Alan Ohnsman Forbes Why The U.S. Should Copy Canada To Fix Its Broken Air Traffic Control System By Jeremy Bogaisky

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?
Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?

Yahoo

time32 minutes ago

  • Yahoo

Is CRISPR Therapeutics (CRSP) a Buy as Wall Street Analysts Look Optimistic?

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important? Let's take a look at what these Wall Street heavyweights have to say about CRISPR Therapeutics AG (CRSP) before we discuss the reliability of brokerage recommendations and how to use them to your advantage. CRISPR Therapeutics currently has an average brokerage recommendation (ABR) of 1.88, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 27 brokerage firms. An ABR of 1.88 approximates between Strong Buy and Buy. Of the 27 recommendations that derive the current ABR, 15 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 55.6% and 3.7% of all recommendations. Check price target & stock forecast for CRISPR Therapeutics here>>> The ABR suggests buying CRISPR Therapeutics, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation. Do you wonder why? As a result of the vested interest of brokerage firms in a stock they cover, their analysts tend to rate it with a strong positive bias. According to our research, brokerage firms assign five "Strong Buy" recommendations for every "Strong Sell" recommendation. In other words, their interests aren't always aligned with retail investors, rarely indicating where the price of a stock could actually be heading. Therefore, the best use of this information could be validating your own research or an indicator that has proven to be highly successful in predicting a stock's price movement. Zacks Rank, our proprietary stock rating tool with an impressive externally audited track record, categorizes stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), and is an effective indicator of a stock's price performance in the near future. Therefore, using the ABR to validate the Zacks Rank could be an efficient way of making a profitable investment decision. In spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures. Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5. Analysts employed by brokerage firms have been and continue to be overly optimistic with their recommendations. Since the ratings issued by these analysts are more favorable than their research would support because of the vested interest of their employers, they mislead investors far more often than they guide. In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research. Furthermore, the different grades of the Zacks Rank are applied proportionately across all stocks for which brokerage analysts provide earnings estimates for the current year. In other words, at all times, this tool maintains a balance among the five ranks it assigns. Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements. Looking at the earnings estimate revisions for CRISPR Therapeutics, the Zacks Consensus Estimate for the current year has remained unchanged over the past month at -$5.54. Analysts' steady views regarding the company's earnings prospects, as indicated by an unchanged consensus estimate, could be a legitimate reason for the stock to perform in line with the broader market in the near term. The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #3 (Hold) for CRISPR Therapeutics. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> It may therefore be prudent to be a little cautious with the Buy-equivalent ABR for CRISPR Therapeutics. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research

5 Must-Read Analyst Questions From Manitowoc's Q1 Earnings Call
5 Must-Read Analyst Questions From Manitowoc's Q1 Earnings Call

Yahoo

time32 minutes ago

  • Yahoo

5 Must-Read Analyst Questions From Manitowoc's Q1 Earnings Call

Manitowoc's first quarter saw a positive market reaction despite revenue and adjusted EPS falling short of Wall Street expectations. Management attributed the quarter's performance to higher orders in the Americas and a sharp uptick in European tower crane demand, with CEO Aaron Ravenscroft highlighting non-new machine sales growth and 'strong customer feedback' at the Bauma trade show. The company also pointed to successful integration of AI into its operational processes, yielding measurable savings, and reported progress in aftermarket initiatives driven by expanded service capabilities. Challenges such as lower overall sales and margin compression were acknowledged, but management focused on the resilience of the aftermarket business and improving order trends. Is now the time to buy MTW? Find out in our full research report (it's free). Revenue: $470.9 million vs analyst estimates of $482 million (4.9% year-on-year decline, 2.3% miss) Adjusted EPS: -$0.16 vs analyst expectations of -$0.09 (71% miss) Adjusted EBITDA: $21.7 million vs analyst estimates of $16.14 million (4.6% margin, 34.4% beat) Operating Margin: 1.3%, down from 3.1% in the same quarter last year Backlog: $793.7 million at quarter end, down 18.3% year on year Market Capitalization: $433.8 million While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Jerry Revich (Goldman Sachs) asked how tariff mitigation splits between pricing, sourcing, and vendor negotiations. CEO Aaron Ravenscroft explained mitigation involves surcharges, alternative suppliers, and partial cost-sharing with vendors, but emphasized the situation is fluid due to currency and market factors. Revich (Goldman Sachs) inquired about the relative impact of Chinese tariffs and underlying assumptions. Ravenscroft declined to break down the exact China portion, noting tariffs affect both Chinese components and steel/aluminum imports, with mitigation strategies dynamically adjusted as tariffs evolve. Revich (Goldman Sachs) sought detail on the drivers behind accelerating European tower crane orders. Ravenscroft described recovery as broad-based, attributing it to historically low dealer inventories and modest improvements in customer sentiment, but clarified that the market remains far from prior cycle peaks. Steven Fisher (UBS) pressed for clarity on the impact of steel and aluminum tariffs on U.S. production costs. Ravenscroft confirmed these are included in the $45 million estimate for Shady Grove manufacturing, reflecting higher input costs for domestically produced cranes. Fisher (UBS) questioned the ability to reprice backlog orders and sustain non-new machine sales growth. Ravenscroft responded that surcharges are intended to offset tariffs on backlog units, and non-new machine sales growth is 'broad-based' across geographies and product types, supported by ongoing expansion of service technicians and locations. Looking ahead, the StockStory team will be watching (1) the company's ability to sustain aftermarket and non-new machine sales momentum, (2) the effectiveness of tariff mitigation efforts as global trade policy evolves, and (3) continued signs of recovery in European tower crane orders. Execution on service expansion, successful pricing strategies, and progress in key infrastructure projects will also be important markers to track. Manitowoc currently trades at $12.24, up from $8.30 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

The 5 Most Interesting Analyst Questions From Viatris's Q1 Earnings Call
The 5 Most Interesting Analyst Questions From Viatris's Q1 Earnings Call

Yahoo

time32 minutes ago

  • Yahoo

The 5 Most Interesting Analyst Questions From Viatris's Q1 Earnings Call

Viatris' first quarter results for 2025 were met with a positive market response, largely due to strong execution in its global branded portfolio and pipeline advancements, despite revenue coming in below consensus. Management highlighted robust growth in Europe and China, as well as progress in its portfolio of innovative medicines. CEO Scott Smith noted, 'We were particularly pleased with our strong execution and growth in Europe and China this quarter,' attributing operational revenue declines mainly to ongoing remediation at the Indore facility and competition in select generic products. Is now the time to buy VTRS? Find out in our full research report (it's free). Revenue: $3.25 billion vs analyst estimates of $3.28 billion (11.2% year-on-year decline, 0.7% miss) Adjusted EPS: $0.50 vs analyst estimates of $0.49 (2.3% beat) Adjusted EBITDA: $923.5 million vs analyst estimates of $903 million (28.4% margin, 2.3% beat) The company reconfirmed its revenue guidance for the full year of $13.75 billion at the midpoint Management raised its full-year Adjusted EPS guidance to $2.23 at the midpoint, a 1.8% increase EBITDA guidance for the full year is $4.04 billion at the midpoint, in line with analyst expectations Operating Margin: -88.6%, down from 5.6% in the same quarter last year Market Capitalization: $10.7 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. Chris Schott (JPMorgan) asked about the sales ramp and infrastructure for fast-acting meloxicam and the company's ability to mitigate tariff impacts. CEO Scott Smith detailed ongoing U.S. manufacturing expansion and multiple mitigation strategies, while Chief Commercial Officer Corinne Le Goff emphasized the large addressable market for non-opioid pain treatments. Ashwani Verma (UBS) questioned whether Viatris could increase share repurchases beyond current guidance. CEO Scott Smith indicated the company intends to maintain flexibility, potentially exceeding $650 million in buybacks, depending on macro volatility and tariff developments. David Amsellem (Piper Sandler) probed the timeline for Indore facility remediation and the status of another Indian site. Smith confirmed that re-inspection for Indore is targeted mid-year and that all commitments for the Nashik facility have been met, with ongoing dialogue with the FDA. Bhavin Patel (Bank of America) sought clarity on brand versus generic trends and the sustainability of core business growth. CFO Doretta Mistras pointed to brand strength in China and Europe and indicated that generics outside of Indore are performing in line with expectations. Umer Raffat (Evercore) asked about the safety and use case for fast-acting meloxicam, specifically bleeding risks and hospital versus outpatient use. Chief R&D Officer Philippe Martin reported no increased bleeding risk in studies and highlighted broad potential for both hospital and outpatient use. In the coming quarters, the StockStory team will closely watch (1) regulatory progress and launch timelines for fast-acting meloxicam, XULANE LO, and other key pipeline assets, (2) the resolution of manufacturing challenges at the Indore and Nashik sites, and (3) the company's ability to offset potential tariff headwinds through supply chain adjustments. Execution on new product launches and cost-saving initiatives will be critical markers of operational success. Viatris currently trades at $9.12, up from $8.59 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it's free). Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store